Clinical Trial Update: Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CX1739 to reverse opioid-induced respiratory depression while preserving opioid analgesia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Respiratory Depression

Drugs mentioned

• CX1739 (CX1739)

Snippet

Sponsor: RespireRx | Conditions: Opiate Induced Respiratory Depression | Phase 2 | Status: UNKNOWN